Advances in combination therapies based on nanoparticles for efficacious cancer treatment: an analytical report
Serge Mignani1, Maria Bryszewska, Barbara Klajnert-Maculewicz
1Université Paris Descartes, PRES Sorbonne Paris Cité, CNRS UMR 860, Laboratoire de Chimie et de Biochimie pharmacologiques et toxicologique, 45, rue des Saints Pères, 75006 Paris, France.
Abstract:
The main objective of nanomedicine research is the development of nanoparticles as drug delivery systems or drugs per se to tackle diseases as cancer, which are a leading cause of death with developed nations. Targeted treatments against solid tumors generally lead to dramatic regressions, but, unfortunately, the responses are often short-lived due to resistant cancer cells. In addition, one of the major challenges of combination drug therapy (called "cocktail") is the crucial optimization of different drug parameters. This issue can be solved using combination nanotherapy. Nanoparticles developed in oncology based on combination nanotherapy are either (a) those designed to combat multidrug resistance or (b) those used to circumvent resistance to clinical cancer drugs. This review provides an overview of the different nanoparticles currently used in clinical treatments in oncology. We analyze in detail the development of combinatorial nanoparticles including dendrimers for dual drug delivery via two strategic approaches: (a) use of chemotherapeutics and chemosensitizers to combat multidrug resistance and (b) use of multiple cytotoxic drugs. Finally, in this review, we discuss the challenges, clinical outlook, and perspectives of the nanoparticle-based combination therapy in cancer.
Insights
Nanomedicine utilizes nanoparticles for targeted cancer drug delivery, overcoming resistance through combination nanotherapy. This approach enhances treatment efficacy against solid tumors by combining drugs or chemosensitizers.
Area of Science:
- Nanomedicine
- Oncology
- Drug Delivery Systems
Background:
- Cancer remains a leading cause of death, with targeted therapies often facing challenges due to resistant cancer cells.
- Optimizing combination drug therapy (cocktails) presents significant challenges in cancer treatment.
- Nanoparticles offer a promising solution for overcoming drug resistance and improving combination therapy.
Purpose of the Study:
- To review nanoparticles used in clinical oncology treatments.
- To analyze the development of combinatorial nanoparticles, including dendrimers, for dual drug delivery.
- To discuss strategies for combating multidrug resistance and circumventing resistance to existing cancer drugs.
Main Methods:
- Review of existing literature on nanoparticles in clinical oncology.
- Detailed analysis of combinatorial nanoparticle development for dual drug delivery.
- Examination of strategic approaches using chemotherapeutics, chemosensitizers, and multiple cytotoxic drugs.
Main Results:
- Nanoparticles are developed to combat multidrug resistance or circumvent resistance to clinical cancer drugs.
- Combinatorial nanoparticles, such as dendrimers, enable dual drug delivery.
- Two main strategies involve using chemotherapeutics/chemosensitizers or multiple cytotoxic drugs.
Conclusions:
- Nanoparticle-based combination therapy holds significant potential for improving cancer treatment efficacy.
- Further research and development are needed to address challenges and optimize clinical applications.
- The clinical outlook for nanoparticle-based combination therapy in cancer is promising.
Related Concept Videos
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:50Combination Therapies and Personalized Medicine
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:57Targeted Cancer Therapies
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:49Cancer Therapies